Oppenheimer & CO Inc Uro Gen Pharma Ltd. Transaction History
Oppenheimer & CO Inc
- $6.18 Billion
- Q2 2024
A detailed history of Oppenheimer & CO Inc transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 19,323 shares of URGN stock, worth $241,151. This represents 0.01% of its overall portfolio holdings.
Number of Shares
19,323Holding current value
$241,151% of portfolio
0.01%Shares
5 transactions
Others Institutions Holding URGN
# of Institutions
119Shares Held
39.3MCall Options Held
158KPut Options Held
161K-
Rtw Investments, LP New York, NY3.56MShares$44.4 Million1.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.3MShares$41.2 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.08MShares$38.5 Million0.78% of portfolio
-
Great Point Partners LLC Greenwich, CT2.91MShares$36.3 Million12.93% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.45MShares$30.6 Million0.11% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $284M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...